Hairmax Partners with Truemed to Accept FSA/HSA Payments on FDA-Cleared Laser Hair Growth Devices
Hairmax, the global leader in laser hair growth technology, is proud to announce a new partnership with Truemed, enabling customers to use FSA (Flexible Spending Account) and HSA (Health Savings Account) funds to purchase eligible Hairmax hair growth medical devices. This collaboration makes Hairmax's full line of Laser Hair Growth solutions—including Laser Caps, Laser Combs, and Laser Band devices—eligible for payment with pre-tax healthcare dollars. This allows customers to save up to 30% or more instantly compared to traditional out-of-pocket spending.
Hairmax laser devices are classified as FDA-cleared medical devices, clinically proven to treat hereditary hair loss and thinning in both men and women. These medical-grade devices use low-level laser therapy (LLLT), a safe, non-invasive, and drug-free treatment that stimulates hair growth, reverses thinning, and increases density and fullness. Backed by decades of clinical research, Hairmax devices are trusted by physicians and hair restoration experts around the world.
'Our partnership with Truemed aligns with our mission to make medically validated hair growth technology accessible to more people,' said Mike Nassar, President of Hairmax. 'Now, customers can invest in their hair health using pre-tax dollars, making it easier and more affordable to take action against hair loss.'
At Truemed, we're excited to broaden our reach through our partnership with Hairmax, a company that shares our commitment to delivering meaningful, health-focused solutions. This collaboration reflects our mission to make health interventions more accessible by enabling HSA/FSA coverage for eligible products that truly improve lives.' – Chantel Hopper, VP of Customer Success & Marketing at Truemed.
In addition to immediate savings, this partnership offers critical year-end benefits. FSA funds typically follow a 'use-it-or-lose-it' policy and must be spent before December 31st. Consumers looking to maximize the value of their remaining 2025 healthcare benefits now have a unique opportunity to invest in clinically proven hair regrowth before their funds expire.
To take advantage of this opportunity, customers can now select the 'Pay with FSA/HSA' option at checkout on Hairmax.com, where Truemed will seamlessly verify eligibility and process the transaction.
About Hairmax
Hairmax is the pioneer and global leader in laser hair growth technology, with over 24 years of innovation and the most FDA clearances in the industry. Hairmax devices are clinically proven and physician-recommended for the treatment of hereditary hair loss and thinning hair. The brand's comprehensive portfolio includes laser devices, hair care, and supplements designed to restore confidence and support a healthy hair growth journey.
About Truemed
About Us blurb: Over $140 billion in HSA/FSA funds sit untouched, with many account holders unaware that their dollars can be spent on more than just prescriptions, doctor's visits, and traditional 'sick-care.' Truemed helps qualified Americans unlock the full potential of these accounts, enabling them to use pre-tax funds on products that help cure, treat, mitigate, and prevent chronic disease, like fitness equipment, supplements, red light therapy, and more. Truemed's curated marketplace and seamless process make it easier to spend smarter and live healthier. Learn more at www.truemed.com .
Learn more at https://hairmax.com/pages/fsa_hsa
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Abeona Therapeutics, AscellaHealth Partner for Commercialization of ZEVASKYN Gene Therapy
Abeona Therapeutics Inc. (NASDAQ:ABEO) is one of the stocks under $10 to buy now. On July 29, AscellaHealth announced its successful HUB partnership with Abeona Therapeutics in the pre- and post-launch commercialization of ZEVASKYN (prademagene zamikeracel), which is an FDA-approved cell-based gene therapy. The collaboration addresses the clinical, operational, and reimbursement needs of this novel autologous cell-based gene therapy by designing and executing patient-centric, end-to-end solutions. An outcome of this partnership was the development and launch of AbeonaAssist, which is a customized patient support program designed to provide a seamless experience for patients, caregivers, and healthcare providers. A close-up of a staff member counting pills in a pharmaceutical warehouse. ZEVASKYN is the first and only autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa/RDEB. Abeona Therapeutics Inc. (NASDAQ:ABEO) is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening diseases. While we acknowledge the potential of ABEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Moderna Inc (MRNA) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Cost ...
Revenue: $0.1 billion for Q2 2025. Net Loss: $0.8 billion for Q2 2025. Cash and Investments: $7.5 billion at the end of Q2 2025. Cost Reduction: 35% reduction in cost of sales, R&D, and SG&A combined compared to Q2 2024. Operating Expenses Reduction: $581 million reduction in Q2 2025 versus Q2 2024, a 40% year-over-year reduction. Net Product Sales: $114 million, primarily driven by COVID vaccine sales. Total Revenue: $142 million for Q2 2025. Cost of Sales: $119 million, representing 105% of net product sales. R&D Expenses: $700 million, down 43% from last year. SG&A Expenses: $230 million, down 14% year over year. Loss Per Share: $2.13, an improvement from a loss of $3.33 in 2024. 2025 Revenue Projection: Updated to $1.5 billion to $2.2 billion. 2025 R&D Expense Forecast: Lowered to $3.6 billion to $3.8 billion. 2025 Capital Expenditures Projection: Lowered to $300 million. Headcount Reduction: Approximately 10% reduction announced. Warning! GuruFocus has detected 2 Warning Sign with MRNA. Release Date: August 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Moderna Inc (NASDAQ:MRNA) secured three FDA approvals, including mNEXSPIKE, a next-generation COVID vaccine, and mRESVIA for high-risk individuals. The company reported a 35% reduction in combined costs of sales, R&D, and SG&A compared to the second quarter of 2024. Moderna Inc (NASDAQ:MRNA) ended the quarter with $7.5 billion in cash and investments, maintaining a strong financial position. Positive Phase III efficacy data for their flu vaccine was announced, which supports the advancement of their flu and flu-COVID combination programs. The UK Court of Appeal upheld the validity of Moderna's EP'949 patent, which was found to be infringed by Pfizer and BioNTech. Negative Points Moderna Inc (NASDAQ:MRNA) reported a net loss of $825 million for the quarter, although this was an improvement from the previous year. Product sales declined by 38% compared to the second quarter of 2024, primarily due to lower COVID vaccine sales. The company announced a 10% workforce reduction to align costs with current business conditions. There was a $300 million reduction in the high end of their 2025 projected revenue range due to a timing shift of UK COVID shipments. Cost of sales represented 105% of net product sales this quarter, up from 62% in the prior year, driven by lower volume. Q & A Highlights Q: Can you explain the rationale behind adding secondary endpoints to the CMV study and provide an update on the individualized neoantigen therapy data cadence? A: Stephen Hoge, President: The addition of secondary endpoints in the CMV study aims to capture more comprehensive data on the vaccine's potential value, such as virus presence in bodily fluids. This is done while the study remains blinded to ensure integrity. Regarding the individualized neoantigen therapy, we expect a consistent cadence of results from randomized studies over the next year or two, starting with the Phase III adjuvant melanoma study. Q: How should we think about COVID vaccine pricing in the US this year compared to last year? A: James Mock, CFO: The US COVID vaccine sales are projected between $1 billion to $1.5 billion, factoring in competitive pressures and vaccination rates. Contracting and pricing are complete, and we are confident in our range, though specific pricing details are not disclosed. Q: What are your expectations for the CMV vaccine's positive readout, and how do you view the regulatory environment with recent FDA and ACIP changes? A: Stephen Hoge, President: A positive CMV readout would show vaccine efficacy above 49.1%, which would significantly impact public health. We continue to have productive dialogues with the FDA and ACIP, and we are grateful for the timely approvals of our recent products. Q: Do you have any early indications of COVID vaccine demand for the upcoming fall and winter season? A: Joseph Stringer, Analyst: Outside the US, demand is stable due to advanced purchase agreements. In the US, the spring booster campaign showed solid uptake, particularly among the 65+ demographic. We remain cautiously optimistic for the fall, but the true demand will be clearer by the end of September. Q: How are you balancing the need to bring late-stage infectious products to market with cost-cutting measures? A: James Mock, CFO: We continue to invest significantly in our late-stage pipeline, focusing on diversification beyond seasonal products. We are balancing the completion of our respiratory portfolio with investments in oncology and rare diseases, while adjusting our cash costs from $9 billion to $4 billion. Q: What does the decision to start the first-line metastatic melanoma trial for Intismeran suggest about the program's potential? A: Stephen Hoge, President: The decision reflects our optimism based on the adjuvant melanoma study results. We believe in the potential of Intismeran in both adjuvant and metastatic settings, supported by our progress in manufacturing efficiency. Q: Can you discuss the flu-COVID combo submission requirements and the timeline for CMV data release? A: Stephen Hoge, President: We are consulting with the FDA on flu-COVID combo requirements, likely needing flu efficacy data first. For CMV, we are updating the statistical analysis plan and expect to release data this fall, though exact timing depends on completing necessary approvals. Q: How are you approaching business development, particularly in oncology, and what are your plans for the COVID-flu combo filing? A: Stephane Bancel, CEO: We focus on partnering for non-mRNA assets and are open to collaborations that enhance our oncology capabilities. For the COVID-flu combo, we may proceed with flu approval first, but concurrent submissions are possible depending on regulatory guidance. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Politico
8 hours ago
- Politico
Senate passes first funding package ahead of shutdown cliff
'It's taken a great deal of work, good faith and negotiation to get to this point,' Senate Appropriations Chair Susan Collins (R-Maine). 'Congress has a responsibility, a constitutional responsibility under Article I, for the power of the purse. We are executing that responsibility.' The package would provide almost $154 billion for military construction and veterans programs. It would send more than $27 billion to the Agriculture department and FDA. Both represent a roughly 2 percent boost over current levels. The Senate rejected an amendment from Sen. Jeff Merkley, an appropriator and the top Democrat on the Senate Budget Committee, that would bar the rescission, or clawback, of funds in the bill by the White House. Democrats are worried that the administration will send another rescissions package ahead of the fall funding deadline, which would likely implode any hopes of getting a larger funding deal. Still, Sen. Patty Murray, the top Democrat on the Appropriations Committee, defended the smaller deal reached among senators, saying that the package 'rejects damaging cuts from Trump and House Republicans.' The Senate adopted by voice vote an amendment from Democratic Sens. Richard Blumenthal of Connecticut and Alex Padilla of California that would bar the use of any funds in the bill to reduce services provided by the Veterans Crisis Line. Senators rejected other amendments from Democrats including one that would have halted funding of the Agriculture Department reorganization and another to require a report on staffing reductions at the VA. They also rejected amendments from Sens. John Kennedy (R-La.) and Rick Scott (R-Fla.) that would have made deeper cuts to the Agriculture-FDA bill. The chamber also voted 75-21 to reject a proposal from Sen. Ron Johnson of Wisconsin that would bar lawmakers from taking credit for earmarks. It would require the funding to be revoked if a lawmaker were to ever tout their earmarks in interviews, mailings, speeches or even on the campaign trail.
